SQZ BIOTECH: UNLEASHING THE POWER OF CELLS

Amy Schulman, Chair of the Board, SQZ Biotech

- **Investment Rational**
  SQZ Biotech is creating powerful, diverse cell therapies that are multifunctional for patients across indications. The company’s unique ability to precision engineer nearly any cell type and deliver multiple materials into cells allows for a potentially safer, more functional, effective, generation of cell therapies.

- **Business Strategy**
  SQZ is developing therapeutics in multiple areas. By addressing patients’ needs across indications, initially focusing on oncology and autoimmune, SQZ is developing a strong pipeline of differentiated therapeutics with significant commercial potential.

- **Core Technology**
  SQZ Biotech generates therapeutics using its propriety Cell Squeeze platform. The cells pass through a constriction which triggers a temporary disruption of the cell membrane allowing for delivery of target materials into the cell. The clinical scale version of the platform engineers over 10B cells in a minute.

- **Product Profile/Pipeline**
  The current SQZ pipeline is initially focused on oncology and immune tolerance. In oncology, SQZ is developing antigen presenting cells (APCs) for solid tumors in partnership with Roche. The first application of SQZ APCs will be in the clinic this year to treat HPV+ tumors. The company plans to expand to additional tumor types with SQZ APCs and has additional proprietary oncology programs in the pipeline.

  In immune tolerance, SQZ is generating Tolerizing Antigen Carriers (TACs) from red blood cells, leveraging the natural mechanism for clearing cells. By inserting antigens associated with immune reactions into TACs, SQZ can piggy-back the tolerance of those antigens on clearing red blood cells. The company’s first application for SQZ TACs is in type 1 diabetes.

- **What’s Next?**
  While SQZ is currently focused on delivering SQZ APCs to the clinic for patients, the company is also developing their long-term plan to apply the SQZ platform to more cell types and addressing more patients. With the breadth of applicability, the team is defining the core value proposition of SQZ, creating therapies that will have the greatest possible impact on patients, both through wholly owned programs and partnerships.